Although tumor necrosis factor (TNF)-Ձ antagonist is a successful treatment modality for various autoimmune dis-eases, including rheumatoid arthritis (RA), ankylosing spon-dylitis and psoriatic arthritis, many adverse effects have been reported. Cutaneous adverse reactions of TNF-Ձ an-tagonist include skin rash, urticaria, lupus like rash, sebor-rheic dermatitis and different kinds of psoriasiform dermatitis. We report a case of psoriasiform dermatitis dur-ing TNF-Ձ antagonist treatment in a 50-year-old woman with RA. The patient has been treated with adalimumab. After 2 months, she developed pruritic erythematous erup-tion and desquamative lesions on the head and limbs, which were defined as psoriasiform change by a skin biopsy. These skin lesions are successfully treated with combination ther-apy, including cessation of adalimumab, corticosteroid and phototherapy.

Keywords: Phototherapy, Psoriasiform dermatitis, TNF-Ձ, antagonist, Rheumatoid arthritis